Double-blind placebo-controlled study of cisapride in patients with nonspecific esophageal motility disorder accompanied by delayed esophageal transit

C. W. Song, Soon-Ho Um, Chang Duck Kim, H. S. Ryu, J. H. Hyun, Jae-Gol Choe

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Nonspecific esophageal motility disorder (NEMD) represents a difficult therapeutic challenge because of the heterogenous nature of the esophageal motor functions. We studied the effects of cisapride on the esophageal symptoms and esophageal motor function in a group of patients with NEMD showing delayed esophageal transit. Methods: Seventy eligible patients were entered into a 4-week, double-blind randomized comparison of 10 mg of cisapride or placebo, four times daily. Symptom assessment, esophageal manometry after wet swallows, and esophageal scintigraphy after intake of a liquid and solid bolus were performed in each patient before and after treatment. Results: After 4 weeks of treatment specific significantly increased the prevalence of esophageal peristaltic contractions (percentage of total contractions, P < 0.05 versus base line and placebo) and significantly improved esophageal emptying of the solid bolus (P < 0.05 versus placebo) but not of the liquid bolus. Placebo did not have any significant effects versus base line on these variables. Both placebo and cisapride improved the distal esophageal amplitude versus base line (no significant intergroup differences). Symptom scores were significantly reduced after 4 weeks of treatment versus base line in both groups (no significant intergroup differences except for heartburn and regurgitation, P < 0.05). On global evaluation of treatment, significantly more patients in the cisapride group were rated as markedly or moderately improved, when compared with placebo. Conclusions: The results of the present study showed that cisapride is effective and well tolerated in patients with NEMD accompanied by delayed esophageal transit. Symptomatic improvement may possibly be related to its beneficial action on the esophageal body by increasing the number of peristaltic contractions and esophageal emptying of solids.

Original languageEnglish
Pages (from-to)541-546
Number of pages6
JournalScandinavian Journal of Gastroenterology
Volume32
Issue number6
Publication statusPublished - 1997 Aug 7

Fingerprint

Esophageal Motility Disorders
Cisapride
Placebos
Swallows
Therapeutics
Heartburn
Symptom Assessment
Manometry
Radionuclide Imaging

Keywords

  • Cisapride
  • Esophageal motility disorder
  • Esophageal peristalsis
  • Esophageal transit
  • Nonspecific esophageal motility disorder

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Double-blind placebo-controlled study of cisapride in patients with nonspecific esophageal motility disorder accompanied by delayed esophageal transit. / Song, C. W.; Um, Soon-Ho; Kim, Chang Duck; Ryu, H. S.; Hyun, J. H.; Choe, Jae-Gol.

In: Scandinavian Journal of Gastroenterology, Vol. 32, No. 6, 07.08.1997, p. 541-546.

Research output: Contribution to journalArticle

@article{406f335ede4e40d28ae1f89dda6b359f,
title = "Double-blind placebo-controlled study of cisapride in patients with nonspecific esophageal motility disorder accompanied by delayed esophageal transit",
abstract = "Background: Nonspecific esophageal motility disorder (NEMD) represents a difficult therapeutic challenge because of the heterogenous nature of the esophageal motor functions. We studied the effects of cisapride on the esophageal symptoms and esophageal motor function in a group of patients with NEMD showing delayed esophageal transit. Methods: Seventy eligible patients were entered into a 4-week, double-blind randomized comparison of 10 mg of cisapride or placebo, four times daily. Symptom assessment, esophageal manometry after wet swallows, and esophageal scintigraphy after intake of a liquid and solid bolus were performed in each patient before and after treatment. Results: After 4 weeks of treatment specific significantly increased the prevalence of esophageal peristaltic contractions (percentage of total contractions, P < 0.05 versus base line and placebo) and significantly improved esophageal emptying of the solid bolus (P < 0.05 versus placebo) but not of the liquid bolus. Placebo did not have any significant effects versus base line on these variables. Both placebo and cisapride improved the distal esophageal amplitude versus base line (no significant intergroup differences). Symptom scores were significantly reduced after 4 weeks of treatment versus base line in both groups (no significant intergroup differences except for heartburn and regurgitation, P < 0.05). On global evaluation of treatment, significantly more patients in the cisapride group were rated as markedly or moderately improved, when compared with placebo. Conclusions: The results of the present study showed that cisapride is effective and well tolerated in patients with NEMD accompanied by delayed esophageal transit. Symptomatic improvement may possibly be related to its beneficial action on the esophageal body by increasing the number of peristaltic contractions and esophageal emptying of solids.",
keywords = "Cisapride, Esophageal motility disorder, Esophageal peristalsis, Esophageal transit, Nonspecific esophageal motility disorder",
author = "Song, {C. W.} and Soon-Ho Um and Kim, {Chang Duck} and Ryu, {H. S.} and Hyun, {J. H.} and Jae-Gol Choe",
year = "1997",
month = "8",
day = "7",
language = "English",
volume = "32",
pages = "541--546",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Double-blind placebo-controlled study of cisapride in patients with nonspecific esophageal motility disorder accompanied by delayed esophageal transit

AU - Song, C. W.

AU - Um, Soon-Ho

AU - Kim, Chang Duck

AU - Ryu, H. S.

AU - Hyun, J. H.

AU - Choe, Jae-Gol

PY - 1997/8/7

Y1 - 1997/8/7

N2 - Background: Nonspecific esophageal motility disorder (NEMD) represents a difficult therapeutic challenge because of the heterogenous nature of the esophageal motor functions. We studied the effects of cisapride on the esophageal symptoms and esophageal motor function in a group of patients with NEMD showing delayed esophageal transit. Methods: Seventy eligible patients were entered into a 4-week, double-blind randomized comparison of 10 mg of cisapride or placebo, four times daily. Symptom assessment, esophageal manometry after wet swallows, and esophageal scintigraphy after intake of a liquid and solid bolus were performed in each patient before and after treatment. Results: After 4 weeks of treatment specific significantly increased the prevalence of esophageal peristaltic contractions (percentage of total contractions, P < 0.05 versus base line and placebo) and significantly improved esophageal emptying of the solid bolus (P < 0.05 versus placebo) but not of the liquid bolus. Placebo did not have any significant effects versus base line on these variables. Both placebo and cisapride improved the distal esophageal amplitude versus base line (no significant intergroup differences). Symptom scores were significantly reduced after 4 weeks of treatment versus base line in both groups (no significant intergroup differences except for heartburn and regurgitation, P < 0.05). On global evaluation of treatment, significantly more patients in the cisapride group were rated as markedly or moderately improved, when compared with placebo. Conclusions: The results of the present study showed that cisapride is effective and well tolerated in patients with NEMD accompanied by delayed esophageal transit. Symptomatic improvement may possibly be related to its beneficial action on the esophageal body by increasing the number of peristaltic contractions and esophageal emptying of solids.

AB - Background: Nonspecific esophageal motility disorder (NEMD) represents a difficult therapeutic challenge because of the heterogenous nature of the esophageal motor functions. We studied the effects of cisapride on the esophageal symptoms and esophageal motor function in a group of patients with NEMD showing delayed esophageal transit. Methods: Seventy eligible patients were entered into a 4-week, double-blind randomized comparison of 10 mg of cisapride or placebo, four times daily. Symptom assessment, esophageal manometry after wet swallows, and esophageal scintigraphy after intake of a liquid and solid bolus were performed in each patient before and after treatment. Results: After 4 weeks of treatment specific significantly increased the prevalence of esophageal peristaltic contractions (percentage of total contractions, P < 0.05 versus base line and placebo) and significantly improved esophageal emptying of the solid bolus (P < 0.05 versus placebo) but not of the liquid bolus. Placebo did not have any significant effects versus base line on these variables. Both placebo and cisapride improved the distal esophageal amplitude versus base line (no significant intergroup differences). Symptom scores were significantly reduced after 4 weeks of treatment versus base line in both groups (no significant intergroup differences except for heartburn and regurgitation, P < 0.05). On global evaluation of treatment, significantly more patients in the cisapride group were rated as markedly or moderately improved, when compared with placebo. Conclusions: The results of the present study showed that cisapride is effective and well tolerated in patients with NEMD accompanied by delayed esophageal transit. Symptomatic improvement may possibly be related to its beneficial action on the esophageal body by increasing the number of peristaltic contractions and esophageal emptying of solids.

KW - Cisapride

KW - Esophageal motility disorder

KW - Esophageal peristalsis

KW - Esophageal transit

KW - Nonspecific esophageal motility disorder

UR - http://www.scopus.com/inward/record.url?scp=0030785773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030785773&partnerID=8YFLogxK

M3 - Article

C2 - 9200284

AN - SCOPUS:0030785773

VL - 32

SP - 541

EP - 546

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 6

ER -